Article

Moore named Iridex interim president, CEO

William M. Moore has been named interim president and chief executive officer of Iridex Corp. Moore succeeds Dominik Beck.

Mountain View, CA-William M. Moore has been named interim president and chief executive officer (CEO) of Iridex Corp. Moore succeeds Dominik Beck, whose employment with the company ceased Aug. 24.

Moore will continue to serve as chairman of the Iridex board of directors during his tenure as interim CEO. He has served as a director of the company since September 2007.

Moore co-founded Natus Medical Inc. in 1990 and served as CEO until 1993. He still serves on the Natus board of directors. Moore also served as a consultant to BlueLine Partners, a private equity firm and investor in Iridex, from February 2004 until June 2008.

Iridex also announced that the board has appointed James Mackaness as chief operating officer, effective immediately. He will continue to serve in his role as the company’s chief financial officer.

In assuming the president and CEO role, Moore indicated that he will lead Iridex’s strategic direction and execution to increase shareholder value, whereas Mackaness will assume more day-to-day operational responsibilities.

For more articles in this issue of Ophthalmology Times eReport, click here.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.